GlassScriptPhysician profile
Lynn E Schneider
NPI 1558371344
$4,292.58
in general payments reported to CMS, 2019-2025
33 companies · $800 in 2025
The $800 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $812 · 2022: $1,007 · 2023: $983 · 2024: $690 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,473.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,355.72 | 2021-2025 | |
| Novo Nordisk INC | $699.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $324.35 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $257.29 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $256.66 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $144.88 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $135.48 | 2021-2022 | |
| Pfizer INC. | $126.73 | 2021-2025 | |
| Amgen INC. | $121.75 | 2021-2024 | Krystexxa, Repatha, Otezla |
| Lundbeck LLC | $94.59 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.64 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $73.32 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $69.29 | 2023-2025 | Abilify Maintena, Rexulti |
| Dexcom, INC. | $63.24 | 2021-2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $58.44 | 2022-2024 | Eliquis, Camzyos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $56.07 | 2023-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $33.52 | 2022 | |
| Sanofi-Aventis U.S. LLC | $28.76 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $26.28 | 2024 | Gemtesa |
| Axsome Therapeutics, INC. | $24.77 | 2024 | Auvelity |
| Phathom Pharmaceuticals, INC. | $24.15 | 2025 | Voquezna |
| Boston Scientific Corporation | $23.90 | 2025 | General - Pain Management |
| Paratek Pharmaceuticals, INC. | $22.93 | 2025 | Nuzyra |
| Sanofi Pasteur INC. | $21.73 | 2023 | |
| Amarin Pharma, INC. | $21.71 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $21.65 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.43 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.23 | 2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $17.82 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.60 | 2023 | Trintellix |
| Abbott Laboratories | $16.14 | 2021 | |
| Daiichi Sankyo INC. | $14.37 | 2021 | |
| Mylan Specialty L.P. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.